Uveitis, an inflammatory disease of the eye, is the third leading cause of blindness in the US, after diabetes and macular degeneration. Autoimmune uveitis is believed to result from an autoimmune reaction to antigens in the eye, specifically the S-antigen and the interphotoreceptor retinoid-binding protein (IRBP). OptiquelT our candidate drug based on ENZ's immune regulation technology platform is a potential therapy for autoimmune uveitis.
There is no known cure for uveitis, a disease that, according to the American Uveitis Society, is newly diagnosed in approximately 38.000 people every year. A particular concern is that it is a major cause of blindness among the younger population, especially in the 25 to 44 age group. Recent research suggests that autoimmune uveitis is significantly under-diagnosed an under-recognized.
While there are steps that can be taken to preserve sight and slow the progress of vision loss, individuals with uveitis are also at increased risks of developing cataracts, glaucoma, or retinal detachment. Current mainstays of therapy, including stestemic steroids and immunosuppressive agents, are associated with significant systemic toxic side effects.
Enzo Biochem, Inc., a life sciences and biotechnology company, engages in the research, development, manufacture, and marketing of diagnostic and research products based on genetic engineering, biotechnology, and molecular biology.
To learn more about ENZ visit: http://www.enzo.com
Marchex, Inc. (Nasdaq:MCHX) announced the availability of a new white paper focusing on digital marketing for small businesses, “Three Things Small Businesses Really Need.” The white paper discusses the challenges and opportunities presented to small businesses in light of the rapid changes in the way consumers are interacting with information online, and how these changes are forcing small business to re-think their approach to marketing.
Marchex, Inc., a performance marketing company, provides call and click-based advertising products to advertisers. The company offers products, services, and technologies that enable advertisers to reach local consumers across online, mobile, and offline sources.
Douglas Lake Minerals Inc. (OTC:DLKM)
Douglas Lake Minerals Inc. recently provided an update regarding its recently acquired Handeni Project which is located in the rapidly developing region of eastern Tanzania. Douglas Lakes' 100% owned Handeni Project consists of four prospecting licenses covering approximately 800 km(2) which are directly adjacent to, and partly surround, Canaco Resources Inc's (V.CAN) 200 km(2) Kilindi license which holds the Magambazi gold mineralization occurrence.
Douglas Lake Successfully Delineates Structural Controls on Gold Mineralization in the Four Handeni Project PLs.
Douglas Lake Minerals Inc. offers gold mining and exploration services. DLKM is based in Surrey, Canada.
To learn more about DLKM visit: http://www.douglaslakeminerals.com
Lakeland Industries Inc. (Nasdaq:LAKE) announced financial results for its third quarter fiscal year 2011 ended October 31, 2010. Financial Results Highlights and Recent Company Developments, Net sales increased $4.0 million, or 18%, to $26.3 million for the three months ended October 31, 2010, from $22.3 million for the three months ended October 31, 2009. The net increase was due to an increase of $2.8 million or 21% in domestic sales and $1.2 million or 14% in foreign sales in the fiscal 2011 quarter as compared with the same quarter of the prior year. External sales from China increased by $2.3 million, or over 100%, driven by domestic sales in China and sale of products for international markets. Canadian sales increased by $0.1 million, or 9.9%, UK sales decreased by 2%, Chile sales decreased by $0.1 million, in part resulting from an earthquake that led to business disruptions, and India sales increased by $0.4 million, or 200%.
Lakeland Industries, Inc. manufactures and sells safety garments and accessories for the industrial protective clothing market primarily in North America, China, India, and Brazil.
Vermillion, Inc. (Nasdaq:VRML) announced that its stockholders approved the reappointment of Gail S. Page, John F. Hamilton and Dr. William C. Wallen as directors of the Company. In addition, shareholders approved the 2010 Stock Incentive Plan and ratified PricewaterhouseCoopers LLP as its independent registered public accounting firm. Gail S. Page joined Vermillion in January 2004. She has been a director since 2005 and currently holds the position of Chief Executive Officer. In this role, she is responsible for leading Vermillion and its development and commercialization of the OVA1 Test. From December 2005 to March 2009, Ms. Page was President and Chief Executive Officer.
Vermillion, Inc. and its subsidiaries engage in the discovery, development, and commercialization of diagnostics tests that help physicians to diagnose and treat patients.
Signup for FREE Daily Stock Alerts From CRWEFinance.com/signup
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEFinance.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEFinance.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://crwefinance.com/disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.